|
GB532822A
(en)
|
1939-08-11 |
1941-01-31 |
John David Kendall |
Improvements in and relating to the production of ª‡-coumarilyl and ª‡-thionaphthenoyl-acetic acid esters
|
|
US4299769A
(en)
|
1980-04-28 |
1981-11-10 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
US4342691A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
US4342689A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
US4342690A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
|
EP0146243A1
(en)
|
1983-10-31 |
1985-06-26 |
Merck Frosst Canada Inc. |
Lipoxygenase inhibitors
|
|
EP0350990B1
(en)
|
1988-07-11 |
1995-09-20 |
Akzo Nobel N.V. |
Pyridazinone derivatives
|
|
US5559127A
(en)
|
1992-10-14 |
1996-09-24 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
|
US5569655A
(en)
|
1993-09-14 |
1996-10-29 |
Sterling Winthrop Inc. |
Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
|
|
US6262055B1
(en)
|
1998-06-03 |
2001-07-17 |
Merck & Co., Inc. |
HIV integrase inhibitors
|
|
EP1086091A4
(en)
|
1998-06-03 |
2001-10-10 |
Merck & Co Inc |
INTEGRASE HIV INHIBITORS
|
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
|
US7288567B2
(en)
|
2000-03-24 |
2007-10-30 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
|
US6448288B1
(en)
|
2000-05-17 |
2002-09-10 |
University Of Massachusetts |
Cannabinoid drugs
|
|
CA2437898A1
(en)
|
2001-02-26 |
2002-09-06 |
Pharma Pacific Pty. Ltd |
Interferon-alpha induced gene
|
|
US7595048B2
(en)
|
2002-07-03 |
2009-09-29 |
Ono Pharmaceutical Co., Ltd. |
Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
|
|
BR0316880A
(pt)
|
2002-12-23 |
2005-10-25 |
Wyeth Corp |
Anticorpos contra pd-1 e usos dos mesmos
|
|
WO2004072286A1
(ja)
|
2003-01-23 |
2004-08-26 |
Ono Pharmaceutical Co., Ltd. |
ヒトｐｄ−１に対し特異性を有する物質
|
|
CN1845914A
(zh)
|
2003-09-02 |
2006-10-11 |
默克公司 |
用于治疗眼压过高的眼用组合物
|
|
EP1740192B1
(en)
|
2004-03-15 |
2012-06-13 |
David K. R. Karaolis |
Cyclic dinucleotide for stimulating the immune of inflammatory response
|
|
EP2439273B1
(en)
|
2005-05-09 |
2019-02-27 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101888321B1
(ko)
|
2005-07-01 |
2018-08-13 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
CN101340909B
(zh)
|
2005-10-18 |
2012-01-11 |
詹森药业有限公司 |
抑制flt3激酶的方法
|
|
EP1782826A1
(en)
|
2005-11-08 |
2007-05-09 |
GBF Gesellschaft für Biotechnologische Forschung mbH |
PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
|
|
NZ594510A
(en)
|
2006-12-27 |
2012-06-29 |
Harvard College |
Compositions and methods for the treatment of infections and tumors
|
|
NZ600758A
(en)
|
2007-06-18 |
2013-09-27 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
MX2011002250A
(es)
|
2008-08-25 |
2011-08-17 |
Amplimmune Inc |
Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
|
|
MX2011003195A
(es)
|
2008-09-26 |
2011-08-12 |
Dana Farber Cancer Inst Inc |
Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
|
|
US8664255B2
(en)
|
2008-10-20 |
2014-03-04 |
The Texas A&M University System |
Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof
|
|
US8217149B2
(en)
|
2008-12-09 |
2012-07-10 |
Genentech, Inc. |
Anti-PD-L1 antibodies, compositions and articles of manufacture
|
|
JP2013512251A
(ja)
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
|
|
WO2012068702A1
(zh)
|
2010-11-23 |
2012-05-31 |
中国医学科学院医药生物技术研究所 |
苯并五元不饱和杂环类化合物及其制备方法
|
|
JP5887947B2
(ja)
|
2011-03-28 |
2016-03-16 |
ソニー株式会社 |
透明導電膜、ヒータ、タッチパネル、太陽電池、有機ｅｌ装置、液晶装置および電子ペーパ
|
|
EP2697242B1
(en)
|
2011-04-13 |
2018-10-03 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
MY193562A
(en)
|
2011-08-01 |
2022-10-19 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
WO2013185052A1
(en)
|
2012-06-08 |
2013-12-12 |
Aduro Biotech |
Compostions and methods for cancer immunotherapy
|
|
EA201590396A1
(ru)
|
2012-12-13 |
2015-12-30 |
Адуро Биотек, Инк. |
Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
|
|
MX365661B
(es)
|
2012-12-19 |
2019-06-10 |
Univ Texas |
Activacion farmaceutica de una senda de señalizacion de di-nucleotido ciclico de mamifero.
|
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
CA2908154C
(en)
|
2013-04-29 |
2023-11-28 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
|
WO2014179760A1
(en)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Cyclic di-nucleotide induction of type i interferon
|
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
JP6400082B2
(ja)
|
2013-05-18 |
2018-10-03 |
アデュロ バイオテック，インコーポレイテッド |
「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法
|
|
RS59500B1
(sr)
|
2013-05-18 |
2019-12-31 |
Aduro Biotech Inc |
Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
|
|
WO2015017652A1
(en)
|
2013-07-31 |
2015-02-05 |
Memorial Sloan-Kettering Cancer Center |
Sting crystals and modulators
|
|
JP2016538344A
(ja)
|
2013-11-19 |
2016-12-08 |
ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ |
癌処置としてのｓｔｉｎｇアゴニストの使用
|
|
US10092644B2
(en)
|
2013-11-22 |
2018-10-09 |
Brock University |
Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
|
|
US9315523B2
(en)
|
2013-12-06 |
2016-04-19 |
Rutgers, The State University Of New Jersey |
Cyclic dinucleosides
|
|
WO2015143712A1
(en)
|
2014-03-28 |
2015-10-01 |
Merck Sharp & Dohme Corp. |
4'-substituted nucleoside reverse transcriptase inhibitors
|
|
US10202411B2
(en)
|
2014-04-16 |
2019-02-12 |
Idenix Pharmaceuticals Llc |
3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
|
|
CN103908468B
(zh)
|
2014-04-21 |
2017-02-08 |
上海捌加壹医药科技有限公司 |
环二核苷酸cGAMP在制备抗肿瘤药物中的应用
|
|
ES2692226T3
(es)
|
2014-06-04 |
2018-11-30 |
Glaxosmithkline Intellectual Property Development Limited |
Dinucleótidos cíclicos como moduladores de STING
|
|
US20170121315A1
(en)
|
2014-06-12 |
2017-05-04 |
Bayer Pharma Aktiengesellschaft |
Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof
|
|
EP3185866A1
(en)
*
|
2014-08-25 |
2017-07-05 |
Pfizer Inc. |
Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
|
|
US20170340658A1
(en)
|
2014-12-16 |
2017-11-30 |
Invivogen |
Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
|
|
ES2764178T3
(es)
|
2014-12-16 |
2020-06-02 |
Kayla Therapeutics |
Dinucleótidos cíclicos fluorados para inducción de citocinas
|
|
CN112626153A
(zh)
|
2014-12-17 |
2021-04-09 |
立博美华基因科技有限责任公司 |
用cGAMP或cGAsMP治疗癌症的方法
|
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
HK1247089A1
(zh)
|
2015-03-10 |
2018-09-21 |
Aduro Biotech, Inc. |
用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
|
|
TW201717968A
(zh)
|
2015-07-14 |
2017-06-01 |
春季銀行製藥公司 |
誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
|
|
US10844051B2
(en)
|
2015-07-22 |
2020-11-24 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Substituted oxazoles for the treatment of cancer
|
|
WO2017019896A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
GEP20207182B
(en)
|
2015-08-13 |
2020-11-25 |
Merck Sharp & Dohme |
Cyclic di-nucleotide compounds as sting agonists
|
|
US9809597B2
(en)
|
2015-08-20 |
2017-11-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
|
|
UY36969A
(es)
|
2015-10-28 |
2017-05-31 |
Novartis Ag |
Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon
|
|
US20170146519A1
(en)
|
2015-11-20 |
2017-05-25 |
Oregon Health & Science University |
Sting agonists and methods of selecting sting agonists
|
|
MX363780B
(es)
|
2015-12-03 |
2019-04-03 |
Glaxosmithkline Ip Dev Ltd |
Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
|
|
DE212016000029U1
(de)
|
2015-12-07 |
2017-07-30 |
Opi Vi - Ip Holdco Llc |
Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
|
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
WO2017123657A1
(en)
|
2016-01-11 |
2017-07-20 |
Gary Glick |
Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
|
|
SMT202500412T1
(it)
|
2016-01-11 |
2025-11-10 |
Innate Tumor Immunity Inc |
Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro
|
|
CN114751950B
(zh)
|
2016-03-18 |
2025-04-18 |
免疫传感器公司 |
环二核苷酸化合物及使用方法
|
|
WO2017175156A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
JOP20170083B1
(ar)
|
2016-04-07 |
2022-03-14 |
Glaxosmithkline Ip Dev Ltd |
أميدات هتيروسيكلية مفيدة كمعدلات بروتين
|
|
PE20190971A1
(es)
|
2016-06-13 |
2019-07-09 |
Glaxosmithkline Ip Dev Ltd |
Compuestos quimicos
|
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
TN2020000158A1
(en)
*
|
2016-10-04 |
2022-04-04 |
Merck Sharp & Dohme |
BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
|